Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | ATM | Q13315 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.36 |
| ▸ | CETP | P11597 | 1/20 | 0.34 |
| ▸ | PREP | P48147 | 3/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30642071 | 1.00 | CHRM2 (0.40) | CHRM2CHRM1CHRM3ALDH1A1ATM | |
| SCHEMBL22454897 | 0.92 | FKBP1A (0.42) | CHRM2CHRM1CHRM3ALDH1A1ATM | |
| SCHEMBL22454898 | 0.92 | FKBP1A (0.42) | CHRM2CHRM1CHRM3ALDH1A1ATM | |
| SCHEMBL30918110 | 0.89 | CHRM2 (0.40) | CHRM2CHRM1CHRM3ALDH1A1FKBP1A | |
| SCHEMBL27380504 | 0.89 | CHRM2 (0.40) | CHRM2CHRM1CHRM3ALDH1A1FKBP1A | |
| SCHEMBL24894588 | 0.89 | CHRM2 (0.40) | CHRM2CHRM1CHRM3ALDH1A1FKBP1A | |
| SCHEMBL24894365 | 0.89 | CHRM2 (0.40) | CHRM2CHRM1CHRM3ALDH1A1FKBP1A | |
| SCHEMBL5368239 | 0.89 | CHRM2 (0.42) | CHRM2CHRM1CHRM3ALDH1A1KMT2A | |
| SCHEMBL18430796 | 0.88 | CHRM2 (0.39) | CHRM2CHRM1CHRM3ALDH1A1ATM | |
| SCHEMBL24894638 | 0.86 | CHRM2 (0.38) | CHRM2CHRM1CHRM3ALDH1A1FKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378216-B2 | Heteroaryl(heterocyclyl)methanol compounds useful in the treatment of hyperglycaemia | ATROGI AB (SE) | 2025-08-05 | — | — | US | disclosed |
| EP-3681862-B1 | BETA-HYDROXY HETEROCYCLIC AMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2023-11-08 | — | — | EP | disclosed |
| US-11427539-B2 | Beta-hydroxy heterocyclic amines and their use in the treatment of hyperglycaemia | ATROGI AB (SE) | 2022-08-30 | — | — | US | disclosed |
| US-20220194920-A1 | HETEROARYL(HETEROCYCLYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2022-06-23 | — | — | US | disclosed |
| US-20220194920-A1 | HETEROARYL(HETEROCYCLYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2022-06-23 | — | — | US | disclosed |
| CN-113784961-A | Heteroaryl (heterocyclyl) carbinol compounds useful for treating hyperglycemia | 阿托基公司 | 2021-12-10 | — | — | CN | disclosed |
| US-20200277259-A1 | BETA-HYDROXY HETEROCYCLIC AMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2020-09-03 | — | — | US | disclosed |
| WO-2019053425-A1 | BETA-HYDROXY HETEROCYCLIC AMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2019-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200277259-A1 | BETA-HYDROXY HETEROCYCLIC AMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | SLC5A1, GPR119, SLC5A2 | CHRM2 756/4885CHRM1 314/4885CHRM3 1396/4885 |
| US-11427539-B2 | Beta-hydroxy heterocyclic amines and their use in the treatment of hyperglycaemia | SLC5A1, GPR119, SLC5A2 | CHRM2 756/4885CHRM1 314/4885CHRM3 1396/4885 |
| US-12378216-B2 | Heteroaryl(heterocyclyl)methanol compounds useful in the treatment of hyperglycaemia | SLC5A1, GPR119, SLC5A2 | CHRM2 353/4885CHRM1 145/4885CHRM3 855/4885 |
| US-20220194920-A1 | HETEROARYL(HETEROCYCLYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA | SLC5A1, GPR119, SLC5A2 | CHRM2 353/4885CHRM1 145/4885CHRM3 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.